ondasdechoque.org
PT-BR

How shockwaves might act in knee osteoarthritis: a 2020 narrative review · Lab study · 2020

How might shockwave act in an arthritic knee?

This review gathers rat, horse and cell studies to explain how shockwave might act in knee arthritis. In rats, treatment was followed by less cartilage breakdown, changes in the bone under the cartilage and fewer pain-signalling nerve cells. Which settings work best is not yet known.

Explores how shockwave works
areas explored: cartilage, the bone beneath it and pain nerves
3
studies in people, described in words only
4
year published
2020

Good to know: A narrative review.

An S, Li J, Xie W, et al. Bioscience Reports, 2020 · Read the paper ↗

The treatment

Device types described
Electrohydraulic, electromagnetic and piezoelectric focused sources and a radial (pneumatic) source are described in general terms. Figure 1 shows a radial pressure-wave device and its pressure-time curve, adapted from another paper. The review gives no clinical treatment protocol.
Animal exposures
Only one animal dose is given: 800 impulses at 14 kV in a rat anterior cruciate ligament transection model. Other animal and cell exposures are not reported in the review.
Clinical regimens
Not reported, except that one cited randomised trial gave weekly shockwaves for 8 weeks alongside isokinetic exercise.

Who took part

Rats with surgically damaged knees, horses with joint arthritis and human cartilage cells grown in the lab.

Side effects

The review does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

No new participants. Mechanistic claims come mainly from rat knee models (anterior cruciate ligament transection, with or without medial meniscectomy, and a meniscal tear model), one rat temporomandibular-joint model, horses with joint osteoarthritis and cultured human chondrocytes. Four clinical studies of knee osteoarthritis are described in words only.

Cartilage changes in animal and cell studies1 reported outcome
01
As reported in the source

Cartilage changes in animal and cell studies

Cartilage changes in animal and cell studies Narrative finding

In rat knee models, the cited studies report lower Mankin scores, less proteoglycan loss and lower CTX-II and MMP levels after treatment; a rat temporomandibular-joint study adds lower MMP-3, MMP-13, cytochrome c and cleaved caspase-3 (markers of cell death). A rat meniscal-tear study reports faster healing in the avascular zone with higher CCN2, SOX9, aggrecan and Col2a1. A cultured-chondrocyte study reports higher CD44 expression, which the authors offer as a reason to combine shockwaves with hyaluronic acid. These are animal and cell results, not measurements of human cartilage.

Analysis details and source

Qualitative finding; no effect estimate. The review says shockwaves restore IL-10 and TNF-α production in chondrocytes to normal, but the title of the cited chondrocyte study reports that both were down-regulated; the primary study was not read.

Subchondral bone changes in rat models1 reported outcome
02
As reported in the source

Subchondral bone changes in rat models

Subchondral bone changes in rat models Narrative finding

In rats after anterior cruciate ligament transection, treatment aimed below the medial tibia was followed by more osteocytes, read by the authors as better bone microarchitecture. In one rat study (ligament transection plus medial meniscectomy), treated rats had better histology, micro-CT and cartilage scores than untreated rats, with higher TGF-β1 and lower DMP-1, MMP-13 and ADAMTS-5; the review takes this to mean that subchondral bone is the better target, although the comparison it reports is with no treatment. The authors also caution that in late-stage disease the same stimulus might promote osteophytes; this concern is speculative and cites a 1991 imaging study of experimental osteoarthritis, not a shockwave study.

Analysis details and source

Qualitative finding; animal model only, no effect estimate.

Pain pathways in animals1 reported outcome
03
As reported in the source

Pain pathways in animals

Pain pathways in animals Narrative finding

Rats with knee osteoarthritis treated on the medial knee had fewer CGRP-positive neurons in the dorsal root ganglia; the authors propose that shockwaves degrade sensory nerve endings and so reduce pain signalling. Horses with carpal, tarsal or metatarsal osteoarthritis treated with shockwaves had mild-to-moderate flexion-test responses, against moderate-to-severe in controls; that source is a veterinary clinical-applications review. No human pain-mechanism data are presented.

Analysis details and source

Qualitative finding; animal studies only, no effect estimate.

Clinical studies cited1 reported outcome
04
As reported in the source

Clinical studies cited

Clinical studies cited Narrative finding

Four knee osteoarthritis studies are summarised in words: shockwaves plus hyaluronic acid versus hyaluronic acid alone; a pilot randomised trial versus kinesiotherapy; a retrospective comparison with laser therapy, with no adverse events in either group; and a four-group randomised trial with exercise, in which only the ultrasound and shockwave groups improved range of motion after treatment and the shockwave group gained most muscle strength. The review concludes that shockwaves relieved pain better than ultrasound in that trial, although the results it describes concern range of motion and strength. No sample sizes, effect sizes or follow-up data are given. The introduction also cites a 2019 systematic review with meta-regression of randomised trials for pain and function, without describing its results.

Analysis details and source

Qualitative summary of cited trials; the review gives no numbers, so none were extracted.

Strength of the authors' conclusions1 reported outcome
05
As reported in the source

Strength of the authors' conclusions

Strength of the authors' conclusions Narrative finding

The introduction states that definite effectiveness in osteoarthritis remains insufficient and the abstract that dosage and frequency are undetermined, yet the conclusion says clinical trials and animal studies have demonstrated efficacy and Figure 2 states that shockwaves could reverse osteoarthritis to some extent. The animal findings support biological plausibility; they do not establish the same effects in human knees.

Analysis details and source

Qualitative appraisal of an internal inconsistency; no effect estimate.

How treatment was delivered
Device types described

Electrohydraulic, electromagnetic and piezoelectric focused sources and a radial (pneumatic) source are described in general terms. Figure 1 shows a radial pressure-wave device and its pressure-time curve, adapted from another paper. The review gives no clinical treatment protocol.

Animal exposures

Only one animal dose is given: 800 impulses at 14 kV in a rat anterior cruciate ligament transection model. Other animal and cell exposures are not reported in the review.

Clinical regimens

Not reported, except that one cited randomised trial gave weekly shockwaves for 8 weeks alongside isokinetic exercise.

HARMS & TOLERABILITY

The review reports no harms data of its own. It mentions negligible complications in other conditions and no adverse events in one retrospective knee study, and raises, without data, a possible risk of promoting bone overgrowth (osteophytes) in late-stage disease. Funding came from National Natural Science Foundation of China and Central South University grants; the authors declare no competing interests, and no device-maker ties are reported.

LIMITS OF THE ANALYSIS

Author-reported: the variety of shockwave methods limits the quality of existing studies, and high-quality studies with standardised parameters are still needed.

Extractor assessment: narrative selection with a declared positive aim, and no search, inclusion criteria or quality appraisal, so contrary studies may be missing.

Extractor assessment: citation problems. The statement that the FDA approved devices for plantar fasciitis and tennis elbow cites a tennis-elbow trial and a shoulder review, not regulatory sources; the IL-10/TNF-α statement differs from the cited study's title.

Extractor assessment: rat, horse and cell findings at experimental doses are extrapolated to human knees without human tissue, imaging or biomarker measurements.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: the variety of shockwave methods limits the quality of existing studies, and high-quality studies with standardised parameters are still needed.
  • Extractor assessment: narrative selection with a declared positive aim, and no search, inclusion criteria or quality appraisal, so contrary studies may be missing.
  • Extractor assessment: citation problems. The statement that the FDA approved devices for plantar fasciitis and tennis elbow cites a tennis-elbow trial and a shoulder review, not regulatory sources; the IL-10/TNF-α statement differs from the cited study's title.
  • Extractor assessment: rat, horse and cell findings at experimental doses are extrapolated to human knees without human tissue, imaging or biomarker measurements.
Research review

Source-linked critical reading

Short narrative review of animal, cell and selected clinical studies of shockwave treatment for knee osteoarthritis. It describes no search method, inclusion criteria, quality appraisal or pooled estimate, and the authors state that they set out to give a positive overview.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Short narrative review of animal, cell and selected clinical studies of shockwave treatment for knee osteoarthritis. It describes no search method, inclusion criteria, quality appraisal or pooled estimate, and the authors state that they set out to give a positive overview.

Participants and setting

No new participants. Mechanistic claims come mainly from rat knee models (anterior cruciate ligament transection, with or without medial meniscectomy, and a meniscal tear model), one rat temporomandibular-joint model, horses with joint osteoarthritis and cultured human chondrocytes. Four clinical studies of knee osteoarthritis are described in words only.

Treatment protocol

Electrohydraulic, electromagnetic and piezoelectric focused sources and a radial (pneumatic) source are described in general terms; Figure 1 shows a radial pressure-wave device and its pressure curve, adapted from another paper. The only animal dose given is 800 impulses at 14 kV in rats. No clinical treatment protocol is given.

Comparison

In the animal work, treated joints are compared with untreated osteoarthritic joints. The four clinical studies used different comparators (hyaluronic acid alone, kinesiotherapy, laser therapy, pulsed ultrasound or exercise alone); the review reports none of their numbers.

What was measured

The review discusses cartilage histology (safranin-O staining, Mankin score), cartilage-breakdown markers (CTX-II, MMP-3, MMP-13), cell-death markers, subchondral bone structure on micro-CT, growth factors (TGF-β1, VEGF), CGRP in pain neurons and, in people, VAS, WOMAC, KOOS, Lequesne index, range of motion and muscle strength. No outcome is measured by the review itself.

Results and interpretation

In rat models, the cited studies report less cartilage breakdown, lower cartilage-degradation markers (CTX-II, MMPs), changes in the bone beneath the cartilage and fewer CGRP-positive pain neurons after treatment. Horses treated for joint osteoarthritis reacted less to flexion tests. In people, the review describes four clinical studies of different designs in words only, without sample sizes or effect sizes, and cites a 2019 systematic review with meta-regression of randomised trials in one sentence without describing its results. The authors themselves write that definite clinical effectiveness remains insufficient and that dosage and frequency are undetermined. One of the four human studies is cited as showing better pain relief than ultrasound, although the results described for it concern range of motion and strength.

Harms and disclosures

The review reports no harms data of its own. It mentions negligible complications in other conditions and no adverse events in one retrospective knee study, and raises, without data, a possible risk of promoting bone overgrowth (osteophytes) in late-stage disease. Funding came from National Natural Science Foundation of China and Central South University grants; the authors declare no competing interests, and no device-maker ties are reported.

Limitations

No search or selection method and a declared positive aim; human studies are summarised without numbers; rat, horse and cell findings are extrapolated to human knees; the FDA statement and the IL-10/TNF-α statement do not match the cited papers. The authors themselves note that varied shockwave methods limit the quality of the existing studies.

Applicability

Explanatory background for clinicians and researchers on how shockwaves might act in osteoarthritic joints. It cannot estimate benefit in people with knee osteoarthritis, recommend a dose or say which patients might respond.

What stronger evidence needs

Controlled human studies that measure cartilage, subchondral bone and pain-pathway changes with imaging or biomarkers, using standardised energy settings, blinded clinical outcomes and long enough follow-up.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shockwave treatment in knee osteoarthritis: therapeutic effects and possible mechanism.

An S, Li J, Xie W, Yin N, Li Y, Hu Y. · Bioscience reports · 2020

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →